.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its top biopharma selection for 2025 and ranked one more 9 labels in the room as overweight. The assets banking company pointed out in a details that it continues to feel “diabesity is set to come to be.